{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:49:05Z","timestamp":1792082945820,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007505","name":"Kirsten og Freddy Johansens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004785","name":"NordForsk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021790","name":"Fondation pour la Recherche sur Alzheimer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021066","name":"Gates Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2017-00915"],"award-info":[{"award-number":["2017-00915"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-00732"],"award-info":[{"award-number":["2022-00732"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["-939721"],"award-info":[{"award-number":["-939721"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["-968270"],"award-info":[{"award-number":["-968270"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["#ALZ2022-0006"],"award-info":[{"award-number":["#ALZ2022-0006"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["-994551"],"award-info":[{"award-number":["-994551"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["-930351"],"award-info":[{"award-number":["-930351"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["-0243"],"award-info":[{"award-number":["-0243"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018713","name":"Center for Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ZEN-21-848495"],"award-info":[{"award-number":["ZEN-21-848495"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["SG-23-1038904 QC"],"award-info":[{"award-number":["SG-23-1038904 QC"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2024-0287"],"award-info":[{"award-number":["FO2024-0287"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018163","name":"Margareta af Ugglas Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.tjpad.2024.100022","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:28:40Z","timestamp":1736504920000},"page":"100022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1360-4834","authenticated-orcid":false,"given":"Sandar","family":"Aye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lannfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-4417","authenticated-orcid":false,"given":"Kristian S","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-1781","authenticated-orcid":false,"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia","family":"Kivipelto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8663-0630","authenticated-orcid":false,"given":"Ron","family":"Handels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Zilka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johannsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-1179","authenticated-orcid":false,"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2024.100022_bib0001","unstructured":"Alzheimer's disease facts and figures. Alzheimers dement, 18. John Wiley & Sons, Ltd; 2022. 2022 Apr [cited 2022 Jun 28]. Available from https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/alz.12638."},{"key":"10.1016\/j.tjpad.2024.100022_bib0002","series-title":"Global estimates on the number of persons across the Alzheimer's disease continuum","author":"Gustavsson","year":"2022"},{"issue":"7","key":"10.1016\/j.tjpad.2024.100022_bib0003","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/alz.12901","article-title":"The worldwide costs of dementia in 2019","volume":"19","author":"Wimo","year":"2023","journal-title":"Alzheimer Dement"},{"issue":"24","key":"10.1016\/j.tjpad.2024.100022_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer's disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.tjpad.2024.100022_bib0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer's disease and other dementias: a priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100022_bib0006","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack Jr","year":"2018","journal-title":"Alzheimer Dement"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100022_bib0007","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2024.100022_bib0008","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2024.100022_bib0009","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2024.100022_bib0010","article-title":"Alzheimer's disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimer Dement: Translat Res Clin Intervent"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100022_bib0011","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab \u2014 binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.tjpad.2024.100022_bib0012","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.tjpad.2024.100022_bib0013","unstructured":"US Food & Drug Administration (FDA). Food & Drug Administration. 2021 [cited 2022 Oct 6]. FDA's Decision to Approve New Treatment for Alzheimer's Disease. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fdas-decision-approve-new-treatment-alzheimers-disease."},{"key":"10.1016\/j.tjpad.2024.100022_bib0014","unstructured":"US Food & Drug Administration (FDA). Food & Drug Administration. 2023 [cited 2023 Sep 22]. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval."},{"issue":"6","key":"10.1016\/j.tjpad.2024.100022_bib0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2024.100022_bib0016","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2024.153","article-title":"Progress in the treatment of Alzheimer's disease is needed \u2013 position statement of European Alzheimer's Disease Consortium (EADC) investigators","author":"Jessen","year":"2024","journal-title":"J Prevent Alzheimer Dis"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100022_bib0017","doi-asserted-by":"crossref","first-page":"398","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimer Dis"},{"issue":"3","key":"10.1016\/j.tjpad.2024.100022_bib0018","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimer Dis"},{"key":"10.1016\/j.tjpad.2024.100022_bib0019","unstructured":"Wilson JJG. Principles and practice of screening for disease. World Health Organization. [Internet]. Geneva; 1968 [cited 2024 Oct 7]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/37650\/WHO_PHP_34.pdf?sequence=17."},{"issue":"36","key":"10.1016\/j.tjpad.2024.100022_bib0020","first-page":"324","article-title":"Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey","volume":"2","author":"Frederiksen","year":"2020","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.tjpad.2024.100022_bib0021","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.tjpad.2024.100022_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect Alzheimer disease in primary care and secondary care","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.tjpad.2024.100022_bib0023","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2024.100022_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00702-021-02449-2","article-title":"Recent update on the heterogeneity of the Alzheimer's disease spectrum","volume":"129","author":"Jellinger","year":"2022","journal-title":"J Neural Transm"},{"issue":"5","key":"10.1016\/j.tjpad.2024.100022_bib0025","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.25333","article-title":"Prevalence of amyloid-\u03b2 pathology in distinct variants of primary progressive aphasia","volume":"84","author":"Bergeron","year":"2018","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100022_bib0026","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/0891988705281883","article-title":"Genetic risk assessment for adult children of people with Alzheimer's disease: The Risk Evaluation and Education for Alzheimer's Disease (REVEAL) Study","volume":"18","author":"Roberts","year":"2005","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100022_bib0027","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100022_bib0028","doi-asserted-by":"crossref","first-page":"e12002","DOI":"10.1002\/trc2.12002","article-title":"Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment","volume":"6","author":"Christensen","year":"2020","journal-title":"Alzheimer Dement (N Y)"},{"issue":"3","key":"10.1016\/j.tjpad.2024.100022_bib0029","article-title":"Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's treatment","volume":"8","author":"Hlavka","year":"2019","journal-title":"Rand Health Q [Internet]"},{"key":"10.1016\/j.tjpad.2024.100022_bib0030","article-title":"Estimates of current capacity for diagnosing Alzheimer's disease in Sweden and the need to expand specialist numbers","author":"Mattke","year":"2023","journal-title":"J Prev Alz Dis"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100022_bib0031","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/alz.12801","article-title":"Clinical performance and robustness evaluation of plasma amyloid-\u03b242\/40 prescreening","volume":"19","author":"Rabe","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2024.100022_bib0032","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/alz.13518","article-title":"Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals","volume":"20","author":"Brum","year":"2024","journal-title":"Alzheimer Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100022_bib0033","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11606-022-07707-x","article-title":"Revisiting the time needed to provide adult primary care","volume":"38","author":"Porter","year":"2023","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.tjpad.2024.100022_bib0034","article-title":"Alzheimer's disease health system readiness \u2013 the time to act is now [Internet]","volume":"390","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.tjpad.2024.100022_bib0035","doi-asserted-by":"crossref","unstructured":"Rosenberg A, Ulf\u00a8ohlund-Wistbacka U, Hall A, Bonnard A, Hagman G, Ryd\u00e9n M, et al. \u03b2-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population. 2022.","DOI":"10.1212\/WNL.0000000000201043"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100022_bib0036","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12877-020-1478-3","article-title":"The MemClin project: a prospective multi memory clinics study targeting early stages of cognitive impairment","volume":"20","author":"Ekman","year":"2020","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.tjpad.2024.100022_bib0037","article-title":"New International Pharmaco-Economic Collaboration on Alzheimer's Disease (IPECAD) Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer's Disease Treatment: development and use cases","author":"Handels","year":"2024","journal-title":"Value in Health"},{"key":"10.1016\/j.tjpad.2024.100022_bib0038","article-title":"Beta-amyloid antibodies for early Alzheimer's disease: effectiveness and value","author":"Lin","year":"2023","journal-title":"Evidence Report. Institute for Clinical and Economic Review"},{"key":"10.1016\/j.tjpad.2024.100022_bib0039","doi-asserted-by":"crossref","unstructured":"Handels R, Wesenhagen K, Tijms B, Teunissen C, Visser P, J\u00f6nsson L. Potential cost-effectiveness of individualized medicine in prodromal Alzheimer's disease by demographic, clinical and cerebrospinal fluid proteomics factors. medRxiv[preprint]. 2023.","DOI":"10.1101\/2023.01.24.23284478"},{"issue":"12","key":"10.1016\/j.tjpad.2024.100022_bib0040","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1016\/j.jval.2023.09.2194","article-title":"MSR136 IPECAD Modeling Workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease and related dementias","volume":"26","author":"Handels","year":"2023","journal-title":"Value in Health"},{"key":"10.1016\/j.tjpad.2024.100022_bib0041","article-title":"People get ready! a new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare","author":"Wahlberg","year":"2023","journal-title":"J Internal Med"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100022_bib0042","doi-asserted-by":"crossref","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimer Res Ther"},{"issue":"6","key":"10.1016\/j.tjpad.2024.100022_bib0043","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat Aging"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100022_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-019-0770-y","article-title":"Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans","volume":"7","author":"Weisov\u00e1","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100022_bib0045","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-020-00948-z","article-title":"Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation","volume":"8","author":"Zilkova","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.tjpad.2024.100022_bib0046","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126355","article-title":"Neurotoxic soluble amyloid oligomers drive alzheimer's pathogenesis and represent a clinically validated target for slowing disease progression","volume":"22","author":"Tolar","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100022_bib0047","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimer Res Ther"},{"issue":"11","key":"10.1016\/j.tjpad.2024.100022_bib0048","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis","volume":"16","author":"Tolar","year":"2020","journal-title":"Alzheimer Dement"},{"issue":"7","key":"10.1016\/j.tjpad.2024.100022_bib0049","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40265-024-02067-8","article-title":"Effects of Oral ALZ-801\/Valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: results of 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early Alzheimer's disease","volume":"84","author":"Hey","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.tjpad.2024.100022_bib0050","first-page":"1","article-title":"Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain","volume":"11","author":"Zhao","year":"2020","journal-title":"Nat Commun [Internet]"},{"issue":"6","key":"10.1016\/j.tjpad.2024.100022_bib0051","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-\/- and LDLr-\/- mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci [Internet]"},{"issue":"5","key":"10.1016\/j.tjpad.2024.100022_bib0052","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-19-0259","article-title":"Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study","volume":"181","author":"Wium-Andersen","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.tjpad.2024.100022_bib0053","doi-asserted-by":"crossref","DOI":"10.1177\/1533317519899546","article-title":"Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS","volume":"35","author":"Akimoto","year":"2020","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"22","key":"10.1016\/j.tjpad.2024.100022_bib0054","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.tjpad.2024.100022_bib0055","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nat Med"},{"issue":"S21","key":"10.1016\/j.tjpad.2024.100022_bib0056","doi-asserted-by":"crossref","DOI":"10.1002\/alz.070865","article-title":"TRAILBLAZER-ALZ 3 \u2013 a deeper dive into time-to-event trials (abstract)","volume":"19","author":"Pugh","year":"2023","journal-title":"Alzheimer Dement"},{"issue":"4","key":"10.1016\/j.tjpad.2024.100022_bib0057","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3-45 study: design of a prevention trial for Alzheimer's disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimer Dement"},{"issue":"9","key":"10.1016\/j.tjpad.2024.100022_bib0058","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer's disease","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.tjpad.2024.100022_bib0059","doi-asserted-by":"crossref","unstructured":"\u00d6hman F, Hassenstab J, Berron D, Sch\u00f6ll M, Papp K V. Current advances in digital cognitive assessment for preclinical Alzheimer's disease. Vol. 13, Alzheimers Dement (Amst). John Wiley and Sons Inc; 2021.","DOI":"10.1002\/dad2.12217"},{"key":"10.1016\/j.tjpad.2024.100022_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14219","article-title":"REAL AD\u2014validation of a realistic screening approach for early Alzheimer's disease","author":"Leuzy","year":"2024","journal-title":"Alzheimer Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:25:06Z","timestamp":1784147106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724006149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2274580724006149"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2024.100022","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2024.100022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100022"}}